Eisai Co., Ltd.｜A human health care company

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

Learn more

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

Learn more
Human Capital Report 2024

Learn more

Human Capital Report 2024

Learn more
Value Creation Report 2024

Learn more

Value Creation Report 2024

Learn more

News Release
Latest News
Information

August 25, 2025

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
August 18, 2025

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
July 31, 2025

Revenue of LEQEMBI® (Preliminary Basis)
July 31, 2025

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease

56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four Years
July 31, 2025

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer’s disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation

August 6, 2025

IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2026 (Webcast)”
August 5, 2025

IR “First Quarter Financial Reports for the Fiscal Year Ending March 31, 2026”
June 19, 2025

About Eisai “Corporate Governance Report”

February 19, 2025

Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”
October 3, 2024

EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024
June 21, 2024

Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
June 3, 2024

The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
April 8, 2024

Eisai Participates in Kakamigahara City’s SDGs Promotion Program through its Activities Including Waste Recycling at the Kawashima Plant

Eisai at a Glance

Eisai Group Worldwide

Eisai's hhc Concept

Innovation

About Eisai

Investors

Sustainability

Sustainability

Making our medicines available to those who need them

32 countries 2.53billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of June 2025)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP